8.68 USD
-0.02 (-0.23%)
8.685 USD
+0.01 (+0.06%)
Taking everything into account, SAGE scores 3 out of 10 in our fundamental rating. SAGE was compared to 525 industry peers in the Biotechnology industry. The financial health of SAGE is average, but there are quite some concerns on its profitability. SAGE is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year SAGE has reported negative net income.
- In the past year SAGE has reported a negative cash flow from operations.
- In the past 5 years SAGE reported 4 times negative net income.
- In the past 5 years SAGE reported 4 times negative operating cash flow.
1.2 Ratios
- SAGE has a Return On Assets of -71.22%. This is in the lower half of the industry: SAGE underperforms 64.07% of its industry peers.
- SAGE has a Return On Equity (-81.68%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -71.22% | ||
| ROE | -81.68% | ||
| ROIC | N/A |
ROA(3y)-57.96%
ROA(5y)-34.18%
ROE(3y)-65.47%
ROE(5y)-38.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 45.16%, SAGE is in the better half of the industry, outperforming 75.50% of the companies in the same industry.
- SAGE's Gross Margin has declined in the last couple of years.
- The Profit Margin and Operating Margin are not available for SAGE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 45.16% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.74%
GM growth 5Y-3.93%
2. Health
2.1 Basic Checks
- SAGE does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, SAGE has more shares outstanding
- Compared to 5 years ago, SAGE has more shares outstanding
- SAGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of -5.35, we must say that SAGE is in the distress zone and has some risk of bankruptcy.
- The Altman-Z score of SAGE (-5.35) is worse than 61.52% of its industry peers.
- SAGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.35 |
ROIC/WACCN/A
WACC11.13%
2.3 Liquidity
- A Current Ratio of 9.16 indicates that SAGE has no problem at all paying its short term obligations.
- SAGE has a Current ratio of 9.16. This is in the better half of the industry: SAGE outperforms 75.32% of its industry peers.
- SAGE has a Quick Ratio of 9.16. This indicates that SAGE is financially healthy and has no problem in meeting its short term obligations.
- SAGE has a better Quick ratio (9.16) than 75.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.16 | ||
| Quick Ratio | 9.16 |
3. Growth
3.1 Past
- SAGE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.60%, which is quite impressive.
- SAGE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -27.58%.
- The Revenue has been growing by 42.99% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)43.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.53%
Revenue 1Y (TTM)-27.58%
Revenue growth 3Y87.07%
Revenue growth 5Y42.99%
Sales Q2Q%265.84%
3.2 Future
- SAGE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.71% yearly.
- Based on estimates for the next years, SAGE will show a very strong growth in Revenue. The Revenue will grow by 40.01% on average per year.
EPS Next Y44.26%
EPS Next 2Y24.68%
EPS Next 3Y19.27%
EPS Next 5Y13.71%
Revenue Next Year93.34%
Revenue Next 2Y66.24%
Revenue Next 3Y54.03%
Revenue Next 5Y40.01%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
- SAGE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SAGE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- SAGE's earnings are expected to grow with 19.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.68%
EPS Next 3Y19.27%
5. Dividend
5.1 Amount
- No dividends for SAGE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SAGE THERAPEUTICS INC / SAGE FAQ
Can you provide the ChartMill fundamental rating for SAGE THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 3 / 10 to SAGE.
What is the valuation status of SAGE THERAPEUTICS INC (SAGE) stock?
ChartMill assigns a valuation rating of 0 / 10 to SAGE THERAPEUTICS INC (SAGE). This can be considered as Overvalued.
Can you provide the profitability details for SAGE THERAPEUTICS INC?
SAGE THERAPEUTICS INC (SAGE) has a profitability rating of 1 / 10.
What is the expected EPS growth for SAGE THERAPEUTICS INC (SAGE) stock?
The Earnings per Share (EPS) of SAGE THERAPEUTICS INC (SAGE) is expected to grow by 44.26% in the next year.